Glioblastoma multiforme (GBM) is one of the most devastating tumors affecting more than 5 in 100,000 people. Unfortunately, its diagnosis is often discovered in late stages and is normally deadly, having a life expectancy of 12–15 months and a mere 3% of the affected patients living 3 years or more independent of race, sex, and age. Sadly, current treatments (i.e., chemotherapy, radiation, surgery) are extremely aggressive and extend the patient’s life by little more than a year on average. Even when treatment appears successful, relapse is often experienced. These extreme treatments, combined with their lack of long-term success, call for new innovations. Among them, nanomedicine becomes one of the most promising approaches regarding possible applications in advancing or ameliorating GBM management. In this chapter, we will therefore analyze the state of the art and the most novel and outstanding innovation in terms of diagnosis and treatment options.

Glioblastoma: State of the Art of Treatments and Applications of Polymeric and Lipidic Nanomedicines / Sgarbi, V.; Duskey, J. T.; Ottonelli, I.; Da Ros, F.; Oddone, N.; Vandelli, M. A.; Forni, F.; Tosi, G.; Ruozi, B.. - 163:(2021), pp. 1-61. [10.1007/978-1-0716-1052-7_1]

Glioblastoma: State of the Art of Treatments and Applications of Polymeric and Lipidic Nanomedicines

Sgarbi V.;Duskey J. T.;Ottonelli I.;Da Ros F.;Oddone N.;Vandelli M. A.;Forni F.;Tosi G.;Ruozi B.
2021

Abstract

Glioblastoma multiforme (GBM) is one of the most devastating tumors affecting more than 5 in 100,000 people. Unfortunately, its diagnosis is often discovered in late stages and is normally deadly, having a life expectancy of 12–15 months and a mere 3% of the affected patients living 3 years or more independent of race, sex, and age. Sadly, current treatments (i.e., chemotherapy, radiation, surgery) are extremely aggressive and extend the patient’s life by little more than a year on average. Even when treatment appears successful, relapse is often experienced. These extreme treatments, combined with their lack of long-term success, call for new innovations. Among them, nanomedicine becomes one of the most promising approaches regarding possible applications in advancing or ameliorating GBM management. In this chapter, we will therefore analyze the state of the art and the most novel and outstanding innovation in terms of diagnosis and treatment options.
Neuromethods
978-1-0716-1051-0
978-1-0716-1052-7
Humana Press Inc.
Glioblastoma: State of the Art of Treatments and Applications of Polymeric and Lipidic Nanomedicines / Sgarbi, V.; Duskey, J. T.; Ottonelli, I.; Da Ros, F.; Oddone, N.; Vandelli, M. A.; Forni, F.; Tosi, G.; Ruozi, B.. - 163:(2021), pp. 1-61. [10.1007/978-1-0716-1052-7_1]
Sgarbi, V.; Duskey, J. T.; Ottonelli, I.; Da Ros, F.; Oddone, N.; Vandelli, M. A.; Forni, F.; Tosi, G.; Ruozi, B.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1226895
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact